HNRNPL facilitates ferroptosis in hepatocellular carcinoma cells by promoting S100A9 expression

  • 0Department of Hepatopancreas Biliary, Hernia Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350005, China; Department of Hepatopancreas Biliary, Hernia Surgery, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350005, China; First Clinical Medical College, Fujian Medical University, Fuzhou, Fujian 350005, China.

|

|

Summary

This summary is machine-generated.

Heterogeneous nuclear ribonucleoprotein L (HNRNPL) promotes ferroptosis in hepatocellular carcinoma (HCC) by stabilizing S100A9 mRNA. This finding reveals a novel mechanism driving HCC progression and offers potential therapeutic targets.

Area Of Science

  • Molecular oncology
  • Cell death pathways
  • Cancer biology

Background

  • Hepatocellular carcinoma (HCC) is a major global health concern with limited effective treatments.
  • Ferroptosis, a regulated form of cell death, is implicated in cancer progression and therapy resistance.
  • The role of specific RNA-binding proteins in regulating ferroptosis in HCC remains incompletely understood.

Purpose Of The Study

  • To investigate the impact of heterogeneous nuclear ribonucleoprotein L (HNRNPL) on ferroptosis in HCC cells.
  • To elucidate the underlying molecular mechanisms by which HNRNPL influences ferroptosis.
  • To evaluate the therapeutic potential of targeting HNRNPL in HCC.

Main Methods

  • Analysis of HNRNPL and S100A9 expression in HCC tissues and cells.
  • In vitro assays measuring cell activity, reactive oxygen species (ROS), iron content, lipid peroxidation (LPO), malondialdehyde (MDA), and glutathione (GSH) levels.
  • RNA immunoprecipitation (RIP), RNA pull-down, and actinomycin D assays to determine HNRNPL-S100A9 interaction and mRNA stability.
  • In vivo xenograft tumor experiments in nude mice.

Main Results

  • HNRNPL and S100A9 were significantly overexpressed in HCC.
  • HNRNPL knockdown decreased HCC cell activity and promoted ferroptosis markers (increased iron, LPO, MDA, ROS; decreased GSH, GPX4, SLC7A11).
  • HNRNPL enhanced S100A9 mRNA stability and expression; S100A9 overexpression or ferroptosis inhibition reversed HNRNPL knockdown effects.
  • In vivo, reduced HNRNPL expression inhibited tumor growth.

Conclusions

  • HNRNPL promotes ferroptosis in HCC cells by increasing S100A9 mRNA stability and expression via RNA-binding protein (RBP) action.
  • Targeting HNRNPL represents a potential therapeutic strategy for hepatocellular carcinoma.
  • This study uncovers a novel regulatory axis in HCC ferroptosis.